All In Biotech

Drug Trial Radar · NCT07884864

A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AHB-121 Injection in Healthy and Chronic Hepatitis B Participants

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Oct 28, 2026

Primary completion

Apr 30, 2027

Study completion Feb 29, 2028

Sponsor

Lead sponsor
Ausper Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AHB-121 injection in healthy and chronic hepatitis B participants.

Conditions

  • Chronic Hepatitis B Virus

Interventions

  • AHB-121Drug

    AHB-121 will be used per week

  • PlaceboDrug

    Placebo will be used per week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety indicatorsTime frame: Up to 18weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.